Ibotta
IBTA
$63.03
+4.44%
Ibotta, Inc. operates a digital promotions platform — the Ibotta Performance Network (IPN) — that connects consumer packaged goods (CPG) brands with consumers through a network of third-party publishers, earning performance-based fees when shoppers redeem offers on promoted grocery and general merchandise products. The company occupies a distinct niche as a performance-marketing intermediary in the retail media ecosystem, monetizing only completed transactions rather than impressions, which differentiates it from traditional advertising networks and positions it as a measurable ROI channel for CPG budgets. The current investor narrative has shifted decisively from post-IPO skepticism to a turnaround-and-acceleration story: after a difficult stretch of decelerating growth and margin pressure, Ibotta's Q3 2026 results (reported November 3, 2026) showed revenue re-acceleration and margin expansion, triggering a single-day rally of more than 30% and pushing the stock to a 183% year-to-date gain. The debate now centers on whether this inflection is durable — whether IPN publisher expansion and CPG budget recovery can sustain double-digit growth against a still-thin GAAP profitability base and a heavily shorted float.…
IBTA
Ibotta
$63.03
Investment Opinion: Should I buy IBTA Today?
Rating: Hold. Ibotta's fundamental inflection is real — Q3 2026 revenue of $97.83M rose 17.49% YoY and built sequentially for three straight quarters ($82.48M → $88.91M → $97.83M), operating margin swung from -13.13% in Q1 to +4.83% in Q3, and TTM free cash flow of $72.42M yields roughly 11% on the $645M market cap — but at $60.35 the stock trades 36% above the $38.43 average analyst target and 19% above even the $49.00 high target, with a consensus of 1 Buy, 6 Hold, 2 Sell (mean 3.22). The business deserves a better multiple than its 1.88x PS trough; the share price has simply gotten there first.
Supporting evidence for holding rather than selling: valuation on sales remains near the bottom of the post-IPO band at 1.88x PS and 3.02x EV/Sales versus 9.73x in Q3 2025 and 12.12x in Q2 2025, meaning the 163.5% YTD rally has been driven by revenue growing into the multiple rather than multiple expansion. Gross margin is stable at 79.85% (78.1% TTM), the balance sheet carries $149.9M cash against debt-to-equity of just 0.089 and a 1.96 current ratio, and buybacks of $13.89M in Q3 and $44.83M in Q1 were funded entirely from internal cash. Consensus 2026 revenue of $425.4M (range $405.9M–$440.8M) is consistent with the Q3 run-rate, and the forward PE of 28.1x on consensus EPS of $0.0749 is demanding but not absurd if the operating leverage continues.
Risks that could invalidate the thesis: first, GAAP profitability is razor-thin — Q3 net income was a -$3.50M loss (EPS -$0.15) because a $9.59M tax expense swamped $6.08M of pre-tax income, leaving a 1.04% trailing net margin and 174.8x trailing PE that offers no earnings cushion. Second, the 20.53% single-session gap on 2.25M shares creates a vacuum toward the $48–$50 pre-earnings zone, and the 45.13% max drawdown shows how violently this name reverses. Third, sell-side targets are stale and bearish — Goldman Sachs has held Sell through July and August 2026 revisions, and the $26.00 low target implies -57%. This Hold would upgrade to Buy on a pullback toward the $45–$50 gap-fill zone or on a wave of post-Q3 target upgrades above $60, and would downgrade to Sell if Q4 revenue fails to hold above the $97.83M Q3 level or operating margin slips back below zero. Verdict: fairly valued to modestly overvalued relative to its own history and clearly ahead of published analyst models, but cheap on sales versus software peers — a stock to own on weakness, not at the top of a 20% gap.
Sign up to view all
IBTA 12-Month Price Forecast
The fundamental case has genuinely improved — three consecutive quarters of sequential revenue growth, a positive operating margin, and an 11% FCF yield at 1.88x sales are the marks of a business that was mispriced at the lows, not one that is mispriced now. But the market has already repriced it: a 163.5% YTD gain, a 20.53% single-session gap, and a price 36% above the average analyst target leave the stock running well ahead of the sell-side's published models, with only 7 analysts covering and no upgrades yet issued despite the blowout quarter. The 11.2 days-to-cover short ratio is genuine upside optionality if targets get revised higher, but it cuts both ways if Q4 disappoints into a vacuum below $50. I would upgrade to bullish on a pullback into the $45–$50 gap-fill zone that preserves the fundamental thesis at a better price, or on confirmed post-Q3 target upgrades above $60; I would downgrade to bearish if Q4 revenue fails to hold the $97.83M Q3 level or if operating margin slips back below zero.
Wall Street consensus
Coverage is thin and cautious: only 7 analysts cover Ibotta, with a distribution of 1 Buy, 6 Hold, and 2 Sell, yielding a consensus recommendation of "hold" (mean rating 3.22 on a 1–5 scale where higher is more bearish). The average target price of $38.43 implies roughly 36% downside from the current $60.35 — a striking disconnect that reflects targets set before the November 3 earnings gap and not yet revised. The consensus clearly leans neutral-to-bearish, and the fact that the stock has blown through every published target suggests analysts are chasing rather than leading the move.
The target range of $26.00 to $49.00 is wide (an 88% spread from low to high), signaling high uncertainty. The high target of $49.00 — still 19% below the current price — would assume sustained revenue acceleration and margin expansion but not the multiple re-rating the market has already delivered; the low target of $26.00 prices in a return to growth deceleration and margin compression. Institutional ratings show a firmly entrenched split: Needham has maintained Buy, Goldman Sachs has maintained Sell through multiple revisions (July and August 2026), while Wells Fargo, Evercore ISI, and UBS remain Neutral/In Line — and notably, the November 3 updates show no upgrades despite the blowout quarter, meaning the post-earnings analyst revisions are likely still pending. With a short ratio of 11.2 days-to-cover, the stock is heavily shorted, and any wave of target upgrades following Q3 could fuel further covering — but the current consensus gap between $38.43 average target and $60.35 price is a clear warning that the market is running well ahead of the sell-side's published models.
Drowning in data?
Find the real signal!
Bulls vs Bears: IBTA Investment Factors
The bull case currently has stronger near-term evidence: revenue built sequentially for three straight quarters to $97.83M, operating margin swung from -13.13% to +4.83%, TTM free cash flow of $72.42M yields roughly 11% on market cap, and the stock trades at just 1.88x sales versus 9-15x through 2025. The bear case rests on price rather than fundamentals: at $60.35 the stock is 36% above the $38.43 average target and 19% above even the highest published target, with a 1.04% net margin and a 20.53% single-day gap that creates a vacuum below. The single most important tension is whether the Q3 inflection is durable — if IPN publisher expansion and CPG budget recovery sustain double-digit sequential growth, the sell-side will be forced to chase and the short ratio of 11.2 days-to-cover becomes fuel; if Q4 shows the sequential build stalling, the stock has no multiple cushion and no analyst support beneath it.
Bullish
- Revenue re-accelerating sequentially: Q3 2026 revenue of $97.83M rose 17.49% YoY and built sequentially from $82.48M in Q1 to $88.91M in Q2 to $97.83M in Q3, the clearest evidence yet that IPN publisher expansion and CPG demand are inflecting. The sequential build is more meaningful than the YoY comparison, which is flattered by a soft Q3 2025 base of $83.26M.
- Operating margin swung positive: Operating income turned positive at $4.72M (4.83% margin) in Q3 2026, a sharp reversal from -$10.83M (-13.13%) in Q1 and -$1.88M (-2.11%) in Q2. This sequential margin recovery is the core of the earnings-beat narrative and shows operating leverage emerging as revenue scales.
- Strong free cash flow and net cash: TTM free cash flow is $72.42M against a $645M market cap, an FCF yield of roughly 11%, with Q3 FCF of $16.78M and operating cash flow of $21.95M. Cash of $149.9M and debt-to-equity of just 0.089 mean the company funds buybacks ($13.89M in Q3, $44.83M in Q1) entirely from internal cash generation.
- Valuation near historical lows on sales: PS of 1.88x and EV/Sales of 3.02x sit far below the 8.7x-15.4x range the stock commanded through 2025 (9.73x in Q3 2025, 12.12x in Q2 2025), even as the share price has more than doubled. The rally has been driven by revenue growing into the multiple rather than multiple expansion, a healthier setup than a pure re-rating.
Bearish
- Price far above every analyst target: The $38.43 average target implies roughly 36% downside from $60.35, and even the $49.00 high target sits 19% below the current price. The consensus is 1 Buy, 6 Hold, 2 Sell (mean 3.22), and the stock has blown through every published target, suggesting the market is running well ahead of sell-side models.
- GAAP profitability is razor-thin: Q3 2026 GAAP net income was a loss of $3.50M (EPS -$0.15) despite $6.08M of pre-tax income, driven by a $9.59M income tax expense. Trailing net margin is just 1.04% and ROE 1.24%, leaving almost no cushion, and the 174.8x trailing PE is economically meaningless on an EPS of $0.0055.
- Parabolic, event-driven price action: The stock gained 45.04% in one month and 70.87% in three months, with a single session adding 20.53% ($50.07 to $60.35) on 2.25M shares. At $60.35 it sits 88.5% of its 52-week range and just 9.1% below its all-time high, and the 45.13% max drawdown shows how violently this name can reverse.
- Growth still modest for the multiple: Revenue growth of 17.49% YoY is respectable but not exceptional, and the forward PE of 28.1x on consensus 2026 EPS of $0.0749 requires earnings to roughly 13x from current levels. If growth re-decelerates, there is limited multiple cushion left given PS is already near the bottom of its post-IPO band.
IBTA Technical Analysis
Ibotta is in a powerful, sustained uptrend that has accelerated into a near-parabolic phase. The stock is up 91.65% over the trailing year and an extraordinary 163.54% year-to-date, and at $60.35 it sits at roughly 88.5% of its 52-week range (low $19.10, high $66.39) — a positioning that signals strong momentum but also meaningful overextension risk, since the stock is trading just 9.1% below its all-time high after a vertical move. The 45.13% maximum drawdown recorded over the period underscores that this is a high-volatility name capable of violent reversals even within a structural uptrend.
Short-term momentum is accelerating rather than decelerating. The stock gained 45.04% in the past month and 70.87% over three months, with the most recent session alone adding 20.53% ($50.07 to $60.35) on the Q3 earnings catalyst — a gap that dwarfs the 6-month gain of 64.08%, confirming the move is back-end loaded and event-driven. Relative strength versus the S&P 500 is extreme across every window: +47.03 points over one month, +72.88 over three months, and +152.92 year-to-date, against a flat-to-negative SPY (-1.99% 1-month, -2.01% 3-month). This is not a beta-driven rally but idiosyncratic alpha; however, a single-day 20% gap on 2.25 million shares of volume creates a vacuum below the gap that often gets tested.
Key technical levels are well defined. Resistance sits at the 52-week high of $66.39 — a breakout above that level would confirm the post-earnings gap as a new base and likely invite momentum and short-covering flows (short ratio of 11.2 days-to-cover signals a heavily shorted float). Support is anchored at the 52-week low of $19.10, but the more actionable near-term support is the pre-earnings consolidation zone around $48–$50, which now serves as the gap-fill floor; a breakdown below that area would signal the earnings pop was a blow-off top. Notably, the reported beta of -0.444 is statistically anomalous for a high-growth software name and likely reflects the stock's short, post-IPO trading history (listed April 2024) rather than genuine inverse market correlation — investors should treat realized volatility, not this beta, as the true risk gauge, and size positions accordingly given the 45% max drawdown.
Beta
—
—
Max Drawdown
-45.1%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
+105.5%
Cumulative gain past year
| Period | IBTA Return | S&P 500 |
|---|---|---|
| 1m | +52.4% | -1.0% |
| 3m | +75.3% | -0.2% |
| 6m | +77.5% | +4.0% |
| 1y | +105.5% | +13.6% |
| ytd | +175.2% | +12.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IBTA Fundamental Analysis
Revenue is re-accelerating after a soft patch. Q3 2026 revenue came in at $97.83 million, up 17.49% year-over-year versus $83.26 million in Q3 2025, and up sequentially from $88.91 million in Q2 2026 and $82.48 million in Q1 2026 — a clear upward trajectory across the last three quarters. The year-over-year comparison is flattered by an easy prior-year base (Q3 2025 revenue of $83.26 million was itself below Q2 2025's $86.03 million), but the sequential build from $82.5M to $88.9M to $97.8M is the more meaningful signal that IPN publisher expansion and CPG demand are inflecting. With consensus 2026 revenue estimated at $425.4 million (range $405.9M–$440.8M), the Q3 print puts the company on track toward the upper half of guidance, supporting the turnaround thesis.
Profitability remains thin but is improving at the operating line. Q3 2026 gross margin was 79.85% (gross profit $78.12 million), consistent with the 78–80% range maintained over the past six quarters and characteristic of a high-margin marketplace platform. However, GAAP net income was a loss of $3.50 million (EPS -$0.15), driven largely by a $9.59 million income tax expense against $6.08 million of pre-tax income — operating income was actually positive at $4.72 million (4.83% operating margin), a sharp swing from Q1 2026's -$10.83 million operating loss and Q2 2026's -$1.88 million. The sequential margin recovery (operating margin from -13.13% in Q1 to -2.11% in Q2 to +4.83% in Q3) is the core of the earnings-beat narrative, though the trailing net margin of just 1.04% leaves little cushion.
Balance sheet and cash generation are solid for a company of this size. Debt-to-equity is only 0.089, the current ratio is 1.96, and cash stood at $149.9 million at quarter-end — ample liquidity against a $645 million market cap. Free cash flow is robust: $72.42 million TTM, with quarterly FCF of $16.78 million in Q3, $8.05 million in Q2, and $27.31 million in Q1, and operating cash flow of $21.95 million in Q3. The company is actively returning capital, repurchasing $13.89 million of stock in Q3 and $44.83 million in Q1, funded entirely from internal cash generation rather than debt. ROE of 1.24% and ROA of -1.20% are weak in absolute terms but reflect a still-early profitability ramp; the FCF yield of roughly 11% on market cap is the strongest fundamental support for the valuation.
Quarterly Revenue
$97825000.0B
2026-09
Revenue YoY Growth
+17.5%
YoY Comparison
Gross Margin
79.8%
Latest Quarter
Free Cash Flow
$72420000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IBTA Overvalued?
Because trailing net income is marginally positive (EPS $0.0055, net margin 1.04%), the PE ratio is technically the primary metric — but at 174.8x trailing it is economically meaningless given the razor-thin earnings base. The more informative lens is the forward PE of 28.1x against consensus 2026 EPS of $0.0749, which implies the market expects earnings to roughly 13x from current levels; the enormous trailing-to-forward gap is the single clearest statement of the market's growth expectations. On a sales basis, the stock trades at just 1.88x trailing PS and 3.02x EV/Sales — remarkably cheap for a 79.9%-gross-margin software platform, reflecting the market's prior skepticism that the Q3 re-acceleration is now beginning to reverse.
Peer comparison is constrained by the absence of a supplied industry-average multiple, but the internal spread is telling: PS of 1.88x and EV/Sales of 3.02x sit far below the 8.7x–15.4x PS range the stock commanded through 2025 (e.g., 9.73x in Q3 2025, 12.12x in Q2 2025), while EV/EBITDA of 26.6x and PCF of 6.77x suggest cash-flow-based metrics are far more supportive than earnings-based ones. The PEG ratio of -1.83 is not meaningful given the near-zero earnings base. Relative to high-growth application software peers that typically trade at 5–10x sales, Ibotta's 1.88x PS represents a substantial discount that is only partially justified by its lower growth rate (17.5% YoY) and thin margins — the discount reflects the market's lingering doubt about durability rather than a structural inferiority.
Historical context is the most striking part of the valuation picture. The stock's PS ratio has compressed from 20.3x in Q4 2024 and 15.4x in Q1 2025 to 1.88x today — near the bottom of its own post-IPO band — even as the share price has more than doubled, because revenue has grown into the multiple. PB of 2.24x is likewise near the low end of its 2.08x–4.37x historical range. This combination — a stock near 52-week highs on price but near historical lows on sales multiple — suggests the rally has been driven by fundamental delivery (revenue growth, margin inflection) rather than multiple expansion, which is a healthier setup; the risk is that if growth re-decelerates, there is limited multiple cushion left to absorb disappointment.
PE
174.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 7x~127x
vs. Industry Avg
31.1x
Industry PE ~31.1x*
EV/EBITDA
26.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on a still-thin profitability base and revenue concentration. Q3 2026 GAAP net income was a loss of $3.50M (EPS -$0.15) because a $9.59M tax expense swamped $6.08M of pre-tax income, and trailing net margin is just 1.04% with ROE of 1.24% and ROA of -1.20%. Revenue is almost entirely performance fees from CPG brands redeeming offers on the IPN, so a pullback in CPG promotional budgets or the loss of a major publisher partner would hit the top line directly; the 17.49% YoY growth also leans on an easy Q3 2025 base of $83.26M. The offset is a fortress-lite balance sheet — $149.9M cash, debt-to-equity of 0.089, current ratio of 1.96, and $72.42M TTM free cash flow — which limits solvency risk but does not protect the earnings multiple.
Market and competitive risks are dominated by valuation compression and the analyst gap. At $60.35 the stock trades 36% above the $38.43 average target and 19% above the $49.00 high target, with a consensus of 1 Buy, 6 Hold, 2 Sell and Goldman Sachs maintaining Sell through July and August 2026 revisions. The forward PE of 28.1x on consensus 2026 EPS of $0.0749 requires earnings to roughly 13x, so any deceleration would compress a multiple that has already been rebuilt from the 1.88x sales trough. The reported beta of -0.444 is statistically anomalous given the April 2024 IPO and should not be relied on as a hedge; realized volatility is the true gauge, evidenced by the 45.13% max drawdown and a 20.53% single-session gap on 2.25M shares. Competitive pressure from larger retail media networks and any CPG budget rotation toward first-party retailer platforms is a structural threat to the IPN intermediary model.
Worst-case scenario: Q4 2026 results show the sequential revenue build stalling below the $97.83M Q3 level, the $9.59M tax-driven net loss repeats, and pending analyst revisions instead cut targets toward the $26.00 low. That combination would fill the post-earnings gap toward the $48-$50 pre-earnings consolidation zone and, if the growth story fully unwinds, retest the $19.10 52-week low — a decline of roughly 68% from $60.35. A more probable adverse path is a retracement to the $38.43 average target, about -36%, or to the $26.00 low target, about -57%. Given the 45.13% max drawdown already recorded, investors should size positions assuming a 35-50% drawdown is a realistic, not tail, outcome.
FAQ
Ranked by severity: first, valuation-versus-target risk — at $60.35 the stock trades 36% above the $38.43 average target and 19% above the $49.00 high target, with a $26.00 low target implying -57%, so there is no analyst support beneath the price. Second, earnings-quality risk — Q3 GAAP net income was a -$3.50M loss because a $9.59M tax expense swamped $6.08M of pre-tax income, leaving a 1.04% net margin and 174.8x trailing PE with essentially no cushion. Third, technical and volatility risk — a 20.53% single-session gap on 2.25M shares creates a vacuum toward $48–$50, and the 45.13% max drawdown shows how violently this name reverses; the reported beta of -0.444 is statistically unreliable given the April 2024 IPO and should not be treated as a hedge. Fourth, business-model concentration — revenue is almost entirely performance fees from CPG brands on the IPN, so a promotional budget pullback or the loss of a major publisher partner would hit the top line directly.
The scenario framework assigns 50% to a base case of $45–$60, 25% to a bull case of $66.39–$80, and 25% to a bear case of $26–$45. The base case assumes Q4 2026 revenue lands near the $97.83M Q3 level, keeping full-year revenue in line with the $425.4M consensus, with operating margin in the 2–5% range and the stock consolidating as analysts gradually lift targets toward the price rather than the price falling to meet them. The bull case requires Q4 revenue above $97.83M with margin above 4.83% plus the still-pending post-earnings target upgrades, which against an 11.2 days-to-cover short ratio could carry shares toward $75–$80. The bear case has Q4 stalling, the tax-driven GAAP loss repeating, and targets cut toward the $26.00 low, filling the gap toward $48–$50 and potentially retesting the $19.10 52-week low, roughly -68%. The base case is most likely, and its key assumption is that the sequential revenue build holds.
The answer depends on the lens. On sales, IBTA looks cheap: 1.88x trailing PS and 3.02x EV/Sales sit far below the 9.73x PS in Q3 2025 and 12.12x in Q2 2025, and below the 5–10x range typical of high-growth application software peers — a discount only partly justified by 17.49% growth and thin margins. On earnings, it looks expensive: trailing PE is 174.8x on EPS of $0.0055 and net margin of 1.04%, while the forward PE of 28.1x on consensus 2026 EPS of $0.0749 requires earnings to roughly 13x from current levels. The market is therefore paying a fair-to-modest premium on cash flow (PCF 6.77x, EV/EBITDA 26.6x) but pricing in a full earnings inflection that has not yet been delivered on a GAAP basis. Relative to its own history the stock is near the bottom of its multiple band; relative to published analyst targets it is clearly ahead of the sell-side's models.
The risk/reward is balanced rather than compelling at $60.35. On the positive side, the business has genuinely inflected — revenue rose 17.49% YoY to $97.83M and built sequentially for three straight quarters, operating margin swung from -13.13% in Q1 to +4.83% in Q3, and $72.42M of TTM free cash flow yields roughly 11% against a $645M market cap. But the price already reflects much of that: the stock is 36% above the $38.43 average analyst target and 19% above even the $49.00 high target, with a 1 Buy / 6 Hold / 2 Sell consensus (mean 3.22) and Goldman Sachs maintaining Sell. The biggest downside risk is a gap-fill toward $48–$50, roughly -20%, or a retest of the $38.43 average target, about -36%, if Q4 revenue fails to hold the Q3 level. It is a reasonable buy for risk-tolerant investors on a pullback into the $45–$50 zone or on confirmed post-Q3 target upgrades above $60 — not at the top of a 20.53% single-session gap.
IBTA is better suited to a long-term holding period of at least 2–3 years than to short-term trading, despite — or because of — its extreme volatility. The stock has gained 163.54% YTD and 91.65% over the trailing year, with a 45.13% max drawdown and a 20.53% single-session gap, so short-term positioning requires timing an event-driven move that has already run 88.5% of its 52-week range and sits just 9.1% below its all-time high. The long-term case rests on the fundamental trajectory: three consecutive quarters of sequential revenue growth, a positive operating margin, $149.9M of cash against debt-to-equity of 0.089, and $72.42M of TTM free cash flow funding buybacks. With no dividend (payout ratio 0) and a forward PE of 28.1x dependent on earnings inflecting roughly 13x, earnings visibility is low and the position should be sized assuming a 35–50% drawdown is realistic; a staged entry on weakness into the $45–$50 zone is preferable to a full position at current levels.